Pharmidex provides comprehensive biomarker and cytokine profiling services to support drug discovery and development across respiratory, autoimmune, metabolic and toxicology programmes. Using state-of-the-art bioanalytical platforms, we deliver robust, translational biomarker data to help understand mechanism of action, immune modulation and therapeutic efficacy. Let’s talk about how our biomarker expertise can strengthen your research. 🌐 https://www.pharmidex.com/BIOMARKERS_ANALYSIS

We’re delighted to share that Vasudha Tandon, PhD Principal Scientist at Pharmidex , will be attending the BBMS Gala Dinner 2026 on Thursday 22 January 2026 at the Old Hall, Queens’ College, Cambridge. This special evening, part of Building Bridges in Medical Sciences, brings together leaders from academia, industry, and healthcare to strengthen collaboration across the life sciences. Vasudha is looking forward to meeting fellow attendees and exploring new opportunities to build meaningful scientific partnerships.

Pharmidex is proud to offer comprehensive in vitro and preclinical solutions tailored to autoimmune disease research, helping accelerate the development of novel treatments. Our expertise spans multiple autoimmune indications including multiple sclerosis, psoriasis, atopic dermatitis, alopecia, colitis, immune response and vitiligo, combining rigorous proof-of-concept studies with integrated pharmacokinetic, pharmacodynamic, biomarkers analysis, histopathological evaluation of relevant organs and tissues, toxicological and bioanalytical endpoints to support fast-track research. With deep scientific knowledge and flexible study designs, we partner with researchers to deliver translationally relevant data that informs confident decision-making throughout the drug discovery and development pathway. If your team is advancing immune-modulating therapies, we’d be delighted to discuss how Pharmidex can help support your research. 🌐 www.pharmidex.com

Pharmidex offers a broad range of pre-clinical respiratory disease models to support drug discovery and development across multiple pulmonary indications. Our capabilities include validated models for asthma (acute, chronic and severe/exacerbation), cough, idiopathic pulmonary fibrosis (IPF), acute lung injury/ARDS, respiratory infections, COPD and allergic rhinitis. These models incorporate clinically relevant triggers and well-established positive controls, enabling robust and translational assessment of novel therapeutics. Our integrated respiratory platforms are designed to help accelerate informed decision-making from early research through to advanced pre-clinical development. If you are developing new therapies for respiratory diseases, we would be pleased to discuss how Pharmidex can support your programme. 🌐 www.pharmidex.com